VTGN
Vistagen Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.17
close · 2026-10-29
value
96
cheaper than peers96
quality
51
stronger fundamentals51
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.31× | 96 |
| EV to EBITDA | 0.28× | 89 |
| price to sales | 4.32× | 78 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 504.9% | 92 |
| debt to equity | 3.2% | 80 |
| operating margin | -904.3% | 24 |
| return on equity | -166.5% | 15 |
4 of 4 measures available
Facts
| market cap | $8M |
| free cash flow | -$37.0M |
| employees | 41 |
| first trade | 2011-06-21 |
| next earnings | 2026-08-14 |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2026 | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.83 | -1.67 | -1.52 | -8.51 | not reported |
| free cash flow | -$66.6M | -$42.3M | -$25.9M | -$49.9M | not reported |
| net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M | not reported |
| revenue | $1.3M | $486,000 | $1.1M | -$227,000 | not reported |
| unusual items | not reported | not reported | not reported | $0 | -$232,000 |